Alessandro Giardino, Giulio Innamorati, Stefano Ugel, Omar Perbellini, Roberto Girelli, Isabella Frigerio, Paolo Regi, Filippo Scopelliti, Giovanni Butturini, Salvatore Paiella, Matilde Bacchion, Claudio Bassi
OBJECTIVE/BACKGROUND: RFA of pancreatic cancer has been demonstrated to be feasible and safe with a positive impact on survival. The aim was to investigate whether an immune reaction is activated after locally advanced pancreatic cancer (LAPC) ablation. METHODS: Peripheral Blood samples were obtained preoperatively and on post-operative days 3-30. Evaluated parameters were: cells [CD4+ , CD8+ and activated subsets, T-Reg, Monocytes, myeloid and plasmocytoid Dendritic cells (mDC and pDC)] and cytokines [Interleukin (IL)-6, Stromal-cells derived factor (SDF)-1, IL-1β, Tumour-Necrosis Factor (TNF)-α, Interferon (IFN)-γ, Vascular Endothelial Growth Factor (VEGF), chemokine (C-C motif) ligand 5 (CCL-5), Transforming-Growth Factor (TGF)-β]...
November 2017: Pancreatology: Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]